About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID 		Trp53
transformation related protein 53
MGI:98834
315 phenotypes from 75 alleles in 88 genetic backgrounds
Export: Excel File
Allelic Composition
Genetic Background		 Annotated Term Reference
Amhr2tm3(cre)Bhr/Amhr2+
Trp53tm2Tyj/Trp53+
involves: 129S4/SvJae * 129S7/SvEvBrd 		normal neoplasm J:222579
Cd19tm1(cre)Cgn/Cd19+
Trp53tm1Yjc/Trp53tm1Yjc
involves: 129P2/OlaHsd * 129S1/Sv * BALB/c * C57BL/6 		normal neoplasm J:195018
Gt(ROSA)26Sortm1(CAG-Trp53*,-EGFP)Medz/Gt(ROSA)26Sor+
Tg(Mx1-cre)1Cgn/0
involves: C57BL/6 * CBA 		abnormal hematopoietic system physiology J:158953
Gt(ROSA)26Sortm1(CAG-Trp53*,-EGFP)Medz/Gt(ROSA)26Sor+
Tg(Nes-cre)1Wme/0
involves: C57BL/6 * CBA 		abnormal hematopoietic system physiology J:158953
normal hematopoietic system phenotype J:158953
Gt(ROSA)26Sortm1(CAG-Trp53*,-EGFP)Medz/Gt(ROSA)26Sortm1(cre/ERT)Nat
involves: 129 * C57BL/6 		abnormal hematopoietic system physiology J:158953
normal hematopoietic system phenotype J:158953
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/?
Trp53tm5Tyj/Trp53tm5Tyj
involves: 129S4/SvJae * C57BL/6 		tumor regression J:118233
Gt(ROSA)26Sortm1.1(CAG-Trp53*,-EGFP)Medz/Gt(ROSA)26Sortm1.1(CAG-Trp53*,-EGFP)Medz
involves: C57BL/6 		decreased thymocyte apoptosis J:158953
Pgrtm2(cre)Lyd/Pgr+
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 		normal reproductive system phenotype J:139053
Tg(CMV-cre)1Cgn/0
Trp53tm2Att/Trp53+
involves: 129S4/SvJae * BALB/cJ 		prenatal lethality, complete penetrance J:131856
Tg(CMV-cre)1Cgn/0
Trp53tm4Att/Trp53+
involves: 129S4/SvJae * BALB/cJ * C57BL/6J 		abnormal atrioventricular cushion morphology J:217080
abnormal cardiac outflow tract development J:217080
abnormal craniofacial morphology J:217080
abnormal inner ear morphology J:217080
abnormal kidney development J:217080
abnormal neural tube closure J:217080
abnormal outer ear morphology J:217080
abnormal skeleton development J:217080
cleft palate J:217080
cleft upper lip J:217080
decreased bone mineral density J:217080
decreased bone mineral density of femur J:217080
decreased bone mineral density of humerus J:217080
decreased cell proliferation J:217080
double outlet right ventricle J:217080
exencephaly J:217080
increased apoptosis J:217080
lethality throughout fetal growth and development, complete penetrance J:217080
persistent truncus arteriosus J:217080
protruding tongue J:217080
retina coloboma J:217080
short humerus J:217080
short mandible J:217080
small kidney J:217080
small thymus J:217080
square face J:217080
ventricular septal defect J:217080
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
Trp53tm1Brn/Trp53tm1Brn
involves: 129 * 129P2/OlaHsd * C57BL/6J * CD-1 * FVB/N 		increased metastatic potential J:136693
increased osteosarcoma incidence J:136693
premature death J:136693
Tg(Tek-cre)1Ywa/0
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * C57BL/6 * CD-1 * SJL 		increased T cell derived lymphoma incidence J:263520
Tg(Trp53)1Srn/0
involves: C57BL/6 * CBA 		decreased incidence of tumors by chemical induction J:80311
decreased tumor incidence J:80311
increased thymocyte apoptosis J:80311
normal mortality/aging J:80311
normal reproductive system phenotype J:80311
Tg(Trp53)1Srn/Tg(Trp53)1Srn
involves: C57BL/6 * CBA 		normal mortality/aging J:80311
Tg(Trp53)1Srn/0
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL/6 * CBA 		decreased thymocyte apoptosis J:80311
premature death J:80311
Tg(Trp53)bSrn/0
involves: C57BL/6 * CBA 		increased thymocyte apoptosis J:80311
Tg(Trp53A135V)L3Ber/0
involves: C57BL/6 * CD-1 		alopecia J:73757
decreased kidney weight J:73757
decreased liver weight J:73757
decreased skeletal muscle mass J:73757
decreased spleen weight J:73757
decreased subcutaneous adipose tissue amount J:73757
decreased testis weight J:73757
decreased tumor incidence J:73757
delayed hair regrowth J:73757
delayed wound healing J:73757
increased lung adenocarcinoma incidence J:73757
increased susceptibility to xenobiotic induced morbidity/mortality J:73757
lethargy J:73757
lordokyphosis J:73757
osteoporosis J:73757
premature aging J:73757
premature death J:73757
ruffled hair J:73757
sparse hair J:73757
weight loss J:73757
Tg(Trp53R172H)8512Jmr/0
involves: FVB 		chromosomal instability J:46426
normal endocrine/exocrine gland phenotype J:46426
increased incidence of tumors by chemical induction J:46426
increased mammary adenocarcinoma incidence J:46426
Tg(Trp53R172L)4491Jmr/0
FVB/N-Tg(Trp53R172L)4491Jmr 		abnormal hair follicle morphology J:56433
abnormal mammary gland growth during lactation J:56433
abnormal mammary gland physiology J:56433
dilated hair follicle J:56433
hair follicle comedo J:56433
lactation failure J:56433
normal neoplasm J:56433
skin lesions J:56433
Tg(Trp53R172L)4491Jmr/0
involves: FVB/N 		abnormal mammary gland growth during lactation J:101547
decreased incidence of tumors by chemical induction J:101547
Trp53Bbl/Trp53+
C57BL/6JSfdAnu-Trp53Bbl/Anu 		increased brain tumor incidence J:104190
increased fibrosarcoma incidence J:104190
increased hemangiosarcoma incidence J:104190
increased lymphoma incidence J:104190
increased osteosarcoma incidence J:104190
increased T cell derived lymphoma incidence J:104190
increased teratoma incidence J:104190
increased tumor incidence J:104190
Trp53Bbl/Trp53Bbl
C57BL/6JSfdAnu-Trp53Bbl/Anu 		increased B cell derived lymphoma incidence J:104190
increased leukemia incidence J:104190
Trp53bhy/Trp53+
C57BL/6JSfdAnu-Trp53bhy/Anu 		increased brain tumor incidence J:104190
increased fibrosarcoma incidence J:104190
increased hemangiosarcoma incidence J:104190
increased lymphoma incidence J:104190
increased osteosarcoma incidence J:104190
increased T cell derived lymphoma incidence J:104190
increased teratocarcinoma incidence J:104190
increased tumor incidence J:104190
Trp53bhy/Trp53bhy
C57BL/6JSfdAnu-Trp53bhy/Anu 		hemorrhage J:104190
increased leukemia incidence J:104190
premature death J:104190
Trp53tm1.1Att/Trp53+
Not Specified 		embryonic lethality during organogenesis, complete penetrance J:96433
Trp53tm1.1Brn/Trp53+
Tg(KRT14-cre)8Brn/?
involves: 129P2/OlaHsd * FVB/N * SKH1 		decreased cellular sensitivity to ultraviolet irradiation J:121734
increased skin tumor incidence J:121734
Trp53tm1.1Brn/Trp53tm1.1Brn
involves: 129P2/OlaHsd * BALB/cJ * FVB/N 		decreased tumor latency J:73028
increased tumor incidence J:73028
Trp53tm1.1Brn/Trp53tm1.1Brn
Tg(KRT14-cre)8Brn/?
involves: 129P2/OlaHsd * FVB/N * SKH1 		decreased cellular sensitivity to ultraviolet irradiation J:121734
increased skin tumor incidence J:121734
Trp53tm1.1Brn/Trp53tm3Tyj
Tg(KRT14-cre)8Brn/?
involves: 129P2/OlaHsd * 129S4/SvJae * FVB/N * SKH1 		decreased cellular sensitivity to ultraviolet irradiation J:121734
increased lymphoma incidence J:121734
increased skin tumor incidence J:121734
Trp53tm1.1Dgj/Trp53tm1.1Dgj
involves: SKH 		decreased cellular sensitivity to ionizing radiation J:162466
decreased cellular sensitivity to ultraviolet irradiation J:162466
normal neoplasm J:162466
Trp53tm1.1Hwan/Trp53+
involves: C57BL/6 * C57BL/6N 		increased incidence of tumors by chemical induction J:265556
Trp53tm1.1Hwan/Trp53tm1.1Hwan
involves: C57BL/6 * C57BL/6N 		increased cellular sensitivity to DNA damaging agents J:265556
increased incidence of tumors by chemical induction J:265556
lethality, incomplete penetrance J:265556
Trp53tm1.1Manf/Trp53tm1.1Manf
involves: C57BL/6J 		abnormal abdominal lymph node morphology J:201153
abnormal cerebellar cortex morphology J:201153
abnormal cerebellar foliation J:201153
abnormal cerebellar Purkinje cell layer J:201153
abnormal definitive hematopoiesis J:201153
abnormal digit pigmentation J:201153
abnormal limb morphology J:201153
abnormal spleen morphology J:201153
abnormal spleen white pulp morphology J:201153
abnormal tail tip morphology J:201153
abnormal thymus morphology J:201153
abnormal tibia morphology J:201153
absent cerebellum vermis J:201153
anemia J:201153
ataxia J:201153
decreased bone marrow cell number J:201153
decreased brain size J:201153
decreased hematopoietic stem cell proliferation J:201153
decreased neutrophil cell number J:201153
enlarged heart J:201153
extramedullary hematopoiesis J:201153
kinked tail J:201153
postnatal growth retardation J:201153
postnatal lethality, complete penetrance J:201153
small spleen J:201153
small thymus J:201153
thin cerebellar granule layer J:201153
thrombocytopenia J:201153
Trp53tm1.1Manf/Trp53tm1.1Manf
Not Specified 		abnormal abdominal lymph node morphology J:201153
abnormal cerebellar cortex morphology J:201153
abnormal cerebellar foliation J:201153
abnormal cerebellar Purkinje cell layer J:201153
abnormal definitive hematopoiesis J:201153
abnormal digit pigmentation J:201153
abnormal limb morphology J:201153
abnormal spleen morphology J:201153
abnormal spleen white pulp morphology J:201153
abnormal tail tip morphology J:201153
abnormal thymus morphology J:201153
abnormal tibia morphology J:201153
absent cerebellum vermis J:201153
anemia J:201153
ataxia J:201153
decreased bone marrow cell number J:201153
decreased brain size J:201153
decreased hematopoietic stem cell proliferation J:201153
decreased neutrophil cell number J:201153
enlarged heart J:201153
extramedullary hematopoiesis J:201153
kinked tail J:201153
postnatal growth retardation J:201153
postnatal lethality, complete penetrance J:201153
small spleen J:201153
small thymus J:201153
thin cerebellar granule layer J:201153
thrombocytopenia J:201153
Trp53tm1.1Mcba/Trp53tm1.1Mcba
involves: 129S6/SvEvTac * C57BL/6 * CD-1 		no abnormal phenotype detected J:150816
Trp53tm1.1Rfo/Trp53+
B6.129P2-Trp53tm1.1Rfo 		normal neoplasm J:186114
Trp53tm1.1Thst/Trp53+
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ 		increased tumor incidence J:198482
premature death J:198482
spleen hyperplasia J:198482
Trp53tm1.1Thst/Trp53tm1.1Thst
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ 		abnormal cell physiology J:198482
decreased cellular sensitivity to gamma-irradiation J:198482
decreased thymocyte apoptosis J:198482
normal immune system phenotype J:198482
increased carcinoma incidence J:198482
increased hemangiosarcoma incidence J:198482
increased leiomyosarcoma incidence J:198482
increased T cell derived lymphoma incidence J:198482
increased tumor incidence J:198482
premature death J:198482
spleen hyperplasia J:198482
Trp53tm1.1Tldo/Trp53+
involves: 129S2/SvPas * BALB/c * C57BL/6 		cardiac hypertrophy J:199308
normal growth/size/body region phenotype J:199308
increased foot pad pigmentation J:199308
increased tail pigmentation J:199308
normal mortality/aging J:199308
Trp53tm1.1Tldo/Trp53tm1.1Tldo
involves: 129S2/SvPas * BALB/c * C57BL/6 		abnormal tongue morphology J:199308
cardiac hypertrophy J:199308
cerebellum hypoplasia J:199308
decreased body size J:199308
decreased bone marrow cell number J:199308
decreased telomere length J:199308
increased foot pad pigmentation J:199308
increased tail pigmentation J:199308
increased thymocyte apoptosis J:199308
nail dystrophy J:199308
oral leukoplakia J:199308
pancytopenia J:199308
postnatal lethality, incomplete penetrance J:199308
premature death J:199308
pulmonary fibrosis J:199308
small gonad J:199308
Trp53tm1.1Umol/Trp53tm1.1Umol
involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac 		decreased tumor latency J:228632
increased B cell derived lymphoma incidence J:228632
increased T cell derived lymphoma incidence J:228632
premature death J:228632
Trp53tm1.1Wgu/Trp53tm1.1Wgu
involves: 129S6/SvEvTac * C57BL/6 		normal cellular phenotype J:186159
decreased cellular sensitivity to gamma-irradiation J:186159
decreased thymocyte apoptosis J:186159
increased fibroblast proliferation J:186159
normal neoplasm J:186159
Trp53tm1.1Xlu/Trp53tm1.1Xlu
involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * FVB/N 		increased incidence of tumors by ionizing radiation induction J:166152
increased liver tumor incidence J:166152
increased lymphoma incidence J:166152
liver hyperplasia J:166152
normal neoplasm J:166152
Trp53tm1.1Xlu/Trp53tm1.1Xlu
involves: 129S6/SvEvTac * C57BL/6 * FVB/N 		normal mortality/aging J:166152
normal neoplasm J:166152
Trp53tm1.2Awbr/Trp53+
involves: C57BL/6 		abnormal lymphocyte morphology J:173271
abnormal Peyer's patch morphology J:173271
extramedullary hematopoiesis J:173271
hepatic steatosis J:173271
increased B cell derived lymphoma incidence J:173271
increased hamartoma incidence J:173271
increased hibernoma incidence J:173271
increased inflammatory response J:173271
increased intestinal adenoma incidence J:173271
increased lung adenoma incidence J:173271
increased osteosarcoma incidence J:173271
increased ovary tumor incidence J:173271
increased tumor incidence J:173271
liver cirrhosis J:173271
liver inflammation J:173271
premature death J:173271
vascular inflammation J:173271
Trp53tm1.2Awbr/Trp53tm1.2Awbr
involves: C57BL/6 		abnormal cell cycle J:173271
abnormal coat/ hair morphology J:173271
abnormal common myeloid progenitor cell morphology J:173271
abnormal lymphocyte morphology J:173271
abnormal Peyer's patch morphology J:173271
absent optic nerve J:173271
adipose tissue inflammation J:173271
decreased cellular sensitivity to gamma-irradiation J:173271
decreased thymocyte apoptosis J:173271
enlarged spleen J:173271
exencephaly J:173271
extramedullary hematopoiesis J:173271
hepatic steatosis J:173271
increased B cell derived lymphoma incidence J:173271
increased brain size J:173271
increased cell proliferation J:173271
increased circulating interferon-gamma level J:173271
increased circulating interleukin-3 level J:173271
increased circulating interleukin-5 level J:173271
increased circulating interleukin-6 level J:173271
increased circulating tumor necrosis factor level J:173271
increased hibernoma incidence J:173271
increased histiocytic sarcoma incidence J:173271
increased inflammatory response J:173271
increased intestinal adenoma incidence J:173271
increased lung adenoma incidence J:173271
increased osteosarcoma incidence J:173271
increased ovary tumor incidence J:173271
increased splenocyte proliferation J:173271
increased T cell derived lymphoma incidence J:173271
increased tumor incidence J:173271
liver cirrhosis J:173271
liver inflammation J:173271
lung inflammation J:173271
premature death J:173271
vascular inflammation J:173271
Trp53tm1Adv/Trp53+
involves: 129S4/SvJae * C57BL/6 		decreased cellular sensitivity to ultraviolet irradiation J:93328
increased skin papilloma incidence J:93328
increased skin tumor incidence J:93328
Trp53tm1Adv/Trp53tm1Adv
involves: 129S4/SvJae * C57BL/6 		decreased cellular sensitivity to ultraviolet irradiation J:93328
increased skin papilloma incidence J:93328
increased skin tumor incidence J:93328
Trp53tm1Att/Trp53+
Tg(KRT5-cre)5132Jlj/0
involves: 129S4/SvJae * C57BL/6J * DBA/2J 		darkened coat color J:139244
increased ear pigmentation J:139244
increased foot pad pigmentation J:139244
increased tail pigmentation J:139244
Trp53tm1Att/Trp53tm1Att
involves: 129S4/SvJae 		abnormal cell cycle J:96433
abnormal cell cycle checkpoint function J:96433
decreased cellular sensitivity to gamma-irradiation J:173395
decreased cellular sensitivity to ultraviolet irradiation J:96433
Trp53tm1Att/Trp53tm1Att
involves: 129S4/SvJae 		abnormal cell cycle J:96433
abnormal cell death J:96433
Trp53tm1Att/Trp53tm1Att
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/?
involves: 129S4/SvJae 		decreased apoptosis J:173395
Trp53tm1b(EUCOMM)Hmgu/Trp53+
C57BL/6N-Trp53tm1b(EUCOMM)Hmgu/H 		decreased circulating creatine kinase level J:211773
Trp53tm1b(EUCOMM)Hmgu/Trp53tm1b(EUCOMM)Hmgu
C57BL/6N-Trp53tm1b(EUCOMM)Hmgu/H 		abnormal retina morphology J:211773
increased large unstained cell number J:211773
increased startle reflex J:211773
persistence of hyaloid vascular system J:211773
preweaning lethality, incomplete penetrance J:211773
Trp53tm1Brd/Trp53+
involves: 129S7/SvEvBrd 		abnormal response to cardiac infarction J:111145
decreased susceptibility to induced morbidity/mortality J:111145
Trp53tm1Brd/Trp53+
involves: 129S7/SvEvBrd * C57BL/6 		decreased neuron apoptosis J:66953
increased carcinoma incidence J:73757
increased lymphoma incidence J:73757
increased osteosarcoma incidence J:73757
increased sarcoma incidence J:73757
increased tumor incidence J:1999, J:73757
Trp53tm1Brd/Trp53tm1Brd
involves: 129S7/SvEvBrd 		abnormal cell cycle J:118244, J:175018
abnormal cell cycle checkpoint function J:78491, J:126186
abnormal cell physiology J:57882, J:110650, J:186159
abnormal chromosome number J:57882
abnormal response to cardiac infarction J:111145
abnormal thymus physiology J:175018
decreased apoptosis J:118602
decreased cellular sensitivity to gamma-irradiation J:78491, J:126186
decreased cellular sensitivity to ionizing radiation J:118602, J:175018
decreased sensitivity to induced cell death J:57882, J:118244, J:126186
decreased susceptibility to induced morbidity/mortality J:111145
decreased thymocyte apoptosis J:186159
decreased tumor-free survival time J:186159
delayed cellular replicative senescence J:175018, J:186159
increased carcinoma incidence J:51661
increased cell proliferation J:110650, J:118602
increased cellular glucose import J:186159
increased fibroblast proliferation J:57882, J:175018, J:186159
increased lymphoma incidence J:51661
increased osteosarcoma incidence J:51661
increased rhabdomyosarcoma incidence J:51661
increased sarcoma incidence J:51661
increased tumor incidence J:108183, J:186159
oxidative stress J:186159
premature death J:109585
Trp53tm1Brd/Trp53tm1Brd
involves: 129S7/SvEvBrd * C57BL/6 		abnormal cell cycle checkpoint function J:126497
decreased apoptosis J:66953, J:108183, J:126497
decreased neuron apoptosis J:66953
increased hemangiosarcoma incidence J:1999
increased lymphoma incidence J:1999
increased osteosarcoma incidence J:1999
increased sarcoma incidence J:1999, J:126497
increased T cell derived lymphoma incidence J:126497
increased tumor incidence J:1999, J:108183
premature death J:1999, J:126497
Trp53tm1Brd/Trp53tm1Brd
NIHOla.129S7-Trp53tm1Brd 		decreased incidence of tumors by chemical induction J:93298
decreased tumor growth/size J:93298
Trp53tm1Brd/Trp53tm1Brd
Tg(Lck-cre)1Cwi/0
involves: 129S7/SvEvBrd 		increased T cell derived lymphoma incidence J:157041
premature death J:157041
Trp53tm1Brd/Trp53tm1Brd
Tg(Nes-cre)1Kln/0
involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * SJL 		increased T cell derived lymphoma incidence J:109585
increased tumor incidence J:109585
premature death J:109585
Trp53tm1Brd/Trp53tm1Ldo
involves: 129S7/SvEvBrd * C57BL/6 		increased sarcoma incidence J:73757
increased T cell derived lymphoma incidence J:73757
increased tumor incidence J:73757
premature death J:73757
Trp53tm1Brd/Trp53tm8Xu
involves: 129S7/SvEvBrd 		abnormal male germ cell apoptosis J:170216
abnormal spermatogenesis J:170216
abnormal spine curvature J:170216
anemia J:170216
decreased body size J:170216
decreased body weight J:170216
decreased bone marrow cell number J:170216
decreased hematopoietic stem cell number J:170216
decreased leukocyte cell number J:170216
decreased neuronal precursor cell number J:170216
increased enterocyte apoptosis J:170216
premature aging J:170216
premature death J:170216
small testis J:170216
Trp53tm1Brn/Trp53+
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129 * 129P2/OlaHsd * C57BL/6J * CD-1 * FVB/N 		increased osteosarcoma incidence J:136693
Trp53tm1Brn/Trp53+
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 		decreased tumor latency J:297725
increased mortality induced by gamma-irradiation J:297725
Trp53tm1Brn/Trp53+
Tg(MMTV-cre)#Tfln/0
involves: 129P2/OlaHsd 		increased mammary adenocarcinoma incidence J:170898
increased mammary gland tumor incidence J:170898
Trp53tm1Brn/Trp53tm1.1Brn
involves: 129P2/OlaHsd 		increased lung adenocarcinoma incidence J:86077, J:157319
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd 		abnormal cell death J:117113
abnormal cell migration J:175978
abnormal cell physiology J:175978
normal cellular phenotype J:117113
enhanced wound healing J:175978
increased lung adenocarcinoma incidence J:86077, J:157319
normal neoplasm J:212578
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * FVB/N 		no abnormal phenotype detected J:73028
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * FVB/N 		ovary cyst J:200783
ovary degeneration J:200783
Trp53tm1Brn/Trp53tm1Brn
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 		decreased tumor latency J:297725
increased mortality induced by gamma-irradiation J:297725
Trp53tm1Brn/Trp53tm1Brn
Tg(Cdh16-cre)91Igr/0
involves: 129P2/OlaHsd * C57BL/6J * FVB/N * ICR 		abnormal corpus epididymis morphology J:215149
abnormal endometrium morphology J:215149
increased endometrial carcinoma incidence J:214850, J:215149
Trp53tm1Brn/Trp53tm1Brn
Tg(Gfap-cre)2Brn/0
involves: 129P2/OlaHsd * FVB/N 		no abnormal phenotype detected J:61961
Trp53tm1Brn/Trp53tm1Brn
Tg(GFAP-cre)25Mes/0
involves: 129P2/OlaHsd * C57BL/6 * FVB/N 		increased astrocytoma incidence J:140704
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT5-cre/PGR)1Der/0
involves: 129P2/OlaHsd * C57BL/6N * FVB/N * ICR 		increased skin squamous cell carcinoma incidence J:216813
normal integument phenotype J:216813
premature death J:216813
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0
involves: 129P2/OlaHsd * FVB/N 		increased mammary adenocarcinoma incidence J:116152
increased mammary gland tumor incidence J:126551
increased pilomatricoma incidence J:116152
increased skin tumor incidence J:116152, J:126551
increased squamous cell carcinoma incidence J:116152
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)105Ayn/0
FVB.Cg-Trp53tm1Brn Tg(MMTV-cre)105Ayn 		increased carcinoma incidence J:165292
increased lung tumor incidence J:165292
increased mammary gland tumor incidence J:165292
increased squamous cell carcinoma incidence J:165292
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)#Mam/0
involves: 129P2/OlaHsd * FVB 		abnormal tumor morphology J:162126
increased lymphoma incidence J:162126
increased mammary gland tumor incidence J:162126
increased tumor incidence J:162126
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)#Tfln/0
involves: 129P2/OlaHsd * C57BL/6 * FVB/N 		increased mammary adenocarcinoma incidence J:224955
increased mammary gland tumor incidence J:224955
increased myoepithelioma incidence J:224955
increased spindle cell carcinoma incidence J:224955
Trp53tm1Brn/Trp53tm1Brn
Tg(Nes-cre/ERT2,-ALPP)1Sbk/0
involves: 129P2/OlaHsd 		increased brain tumor incidence J:237990
increased medulloblastoma incidence J:237990
increased tumor incidence J:237990
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129P2/OlaHsd * C57BL/6 * CD-1 		decreased tumor-free survival time J:319454
increased metastatic potential J:199542
increased osteosarcoma incidence J:199542
premature death J:199542
Trp53tm1Brn/Trp53tm1Brn
Tg(Upk2-cre)1Rkl/0
involves: 129P2/OlaHsd * C57BL/6 * FVB 		normal cardiovascular system phenotype J:173505
normal neoplasm J:173505
normal renal/urinary system phenotype J:173505
Trp53tm1Brn/Trp53tm1Brn
Tg(Wap-cre)51Nki/0
involves: 129P2/OlaHsd * FVB/N 		increased mammary adenocarcinoma incidence J:171765
increased mammary gland tumor incidence J:171765
Trp53tm1Brn/Trp53tm1Tyj
Tg(Nes-cre)1Kln/0
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL 		increased medulloblastoma incidence J:102702
Trp53tm1Brn/Trp53tm2Tyj
involves: 129P2/OlaHsd * 129S4/SvJae 		abnormal cell physiology J:175978
Trp53tm1Elee/Trp53+
Tg(MMTV-cre)AElee/0
involves: 129S4/SvJae * C57BL/6 		increased tumor latency J:90247
Trp53tm1Elee/Trp53tm1Elee
Tg(GFAP-cre)25Mes/0
involves: 129S4/SvJae * FVB/N 		ataxia J:149662
impaired balance J:149662
increased brain size J:149662
increased glioma incidence J:149662
increased medulloblastoma incidence J:149662
increased sarcoma incidence J:149662
normal nervous system phenotype J:149662
premature death J:149662
seizures J:149662
tremors J:149662
Trp53tm1Elee/Trp53tm1Elee
Tg(MMTV-cre)AElee/0
involves: 129S4/SvJae * C57BL/6 		increased lymphoma incidence J:90247
increased mammary adenocarcinoma incidence J:90247
increased mammary gland tumor incidence J:90247
Trp53tm1Elee/Trp53tm1Elee
Tg(MMTV-cre)BElee/0
involves: 129S4/SvJae * C57BL/6 		increased mammary adenocarcinoma incidence J:90247
increased tumor incidence J:90247
Trp53tm1Elee/Trp53tm1Elee
Tg(Wap-rtTA-cre)10Whl/0
involves: 129S4/SvJae * C57BL/6 		increased mammary adenocarcinoma incidence J:90247
increased tumor incidence J:90247
Trp53tm1Elee/Trp53tm1Tyj
Tg(GFAP-cre)25Mes/0
involves: 129S2/SvPas * 129S4/SvJae * FVB/N 		ataxia J:149662
impaired balance J:149662
increased brain size J:149662
increased glioma incidence J:149662
increased medulloblastoma incidence J:149662
increased sarcoma incidence J:149662
normal nervous system phenotype J:149662
premature death J:149662
seizures J:149662
tremors J:149662
Trp53tm1Gev/Trp53tm1Gev
involves: 129P2/OlaHsd * C57BL/6 		decreased cellular sensitivity to gamma-irradiation J:99305
increased T cell derived lymphoma incidence J:99305
Trp53tm1Glo/Trp53+
involves: 129S7/SvEvBrd 		increased carcinoma incidence J:129627
increased lymphoma incidence J:129627
increased osteosarcoma incidence J:129627
increased sarcoma incidence J:129627
increased squamous cell carcinoma incidence J:129627
increased tumor incidence J:129627
Trp53tm1Glo/Trp53+
involves: 129S7/SvEvBrd * C57BL/6 		decreased tumor-free survival time J:61683
increased carcinoma incidence J:61683
increased fibrosarcoma incidence J:61683
increased hemangiosarcoma incidence J:61683
increased lymphoma incidence J:61683
increased metastatic potential J:61683
increased osteosarcoma incidence J:61683
increased sarcoma incidence J:61683
increased squamous cell carcinoma incidence J:61683
increased tumor incidence J:61683
Trp53tm1Glo/Trp53+
involves: 129S7/SvEvBrd * C57BL/6J 		increased incidence of tumors by ionizing radiation induction J:172038
Trp53tm1Glo/Trp53tm1Glo
involves: 129S7/SvEvBrd * C57BL/6 		decreased tumor-free survival time J:61683
increased T cell derived lymphoma incidence J:61683
increased tumor incidence J:61683
Trp53tm1Glo/Trp53tm1Glo
involves: 129S7/SvEvBrd * C57BL/6J 		decreased thymocyte apoptosis J:172038
Trp53tm1Glo/Trp53tm4Glo
involves: 129S7/SvEvBrd * C57BL/6 		abnormal tumor morphology J:171821
decreased tumor-free survival time J:171821
increased adenocarcinoma incidence J:171821
increased lipoma incidence J:171821
increased lymphoma incidence J:171821
increased sarcoma incidence J:171821
increased spindle cell carcinoma incidence J:171821
increased T cell derived lymphoma incidence J:171821
Trp53tm1Glo/Trp53tm4Glo
Tg(CAG-cre/Esr1*)5Amc/0
involves: 129S7/SvEvBrd * C57BL/6 * CBA 		abnormal tumor pathology J:171821
extended life span J:171821
tumor regression J:171821
Trp53tm1Holl/Trp53tm1Holl
involves: 129/Sv * 129P2/OlaHsd * C57BL/6 		normal cellular phenotype J:68918
normal neoplasm J:68918
Trp53tm1Holl/Trp53tm1Holl
involves: 129P2/OlaHsd 		normal cellular phenotype J:126497
Trp53tm1Holl/Trp53tm2Holl
involves: 129P2/OlaHsd 		no abnormal phenotype detected J:135505
Trp53tm1Holl/Trp53tm7.1Xu
involves: 129P2/OlaHsd 		decreased thymocyte apoptosis J:160414
increased tumor incidence J:160414
Trp53tm1Ldo/Trp53+
B6.129S7-Trp53tm1Ldo 		abnormal mammary gland development J:130123
decreased circulating insulin-like growth factor I level J:130123
Trp53tm1Ldo/Trp53+
involves: 129S7/SvEvBrd * C57BL/6 		abnormal cell physiology J:73757
abnormal physiological response to xenobiotic J:73757
decreased bone mineral density J:73757
decreased kidney weight J:73757
decreased liver weight J:73757
decreased skeletal muscle mass J:73757
decreased spleen weight J:73757
decreased subcutaneous adipose tissue amount J:73757
decreased testis weight J:73757
decreased tumor incidence J:73757
delayed hair regrowth J:73757
delayed wound healing J:73757
increased lung adenoma incidence J:73757
increased susceptibility to xenobiotic induced morbidity/mortality J:73757
lethargy J:73757
liver hypoplasia J:73757
lordokyphosis J:73757
muscular atrophy J:73757
premature aging J:73757
premature death J:73757
renal hypoplasia J:73757
sparse hair J:73757
spleen hypoplasia J:73757
testis hypoplasia J:73757
thin dermal layer J:73757
weight loss J:73757
Trp53tm1Manf/Trp53tm1Manf
Not Specified 		no abnormal phenotype detected J:201153
Trp53tm1Mlh/Trp53tm1Mlh
involves: 129P2/OlaHsd 		abnormal cell cycle J:115104
normal cellular phenotype J:115104
decreased enterocyte apoptosis J:54082
Trp53tm1Sia/Trp53tm1Sia
involves: C57BL/6 * CBA 		abnormal cell proliferation J:36762
decreased cellular sensitivity to ultraviolet irradiation J:85569
increased sensitivity to induced cell death J:85569
increased T cell derived lymphoma incidence J:36762
increased tumor incidence J:36762
Trp53tm1Sia/Trp53tm1Sia
involves: C57BL/6NCrlj * CBA/JNCrlj 		increased leukocyte cell number J:233347
increased spleen weight J:233347
increased T cell derived lymphoma incidence J:233347
increased thymus weight J:233347
premature death J:233347
thrombocytopenia J:233347
Trp53tm1Thl/Trp53tm1Thl
Tg(Pbsn-cre)4Prb/0
involves: C57BL/6 * DBA/2 		normal neoplasm J:100683
Trp53tm1Thst/Trp53+
involves: 129S1/Sv * 129X1/SvJ 		increased tumor incidence J:198482
premature death J:198482
spleen hyperplasia J:198482
Trp53tm1Thst/Trp53tm1.1Thst
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ 		increased tumor incidence J:198482
premature death J:198482
spleen hyperplasia J:198482
Trp53tm1Thst/Trp53tm1Thst
involves: 129S1/Sv * 129X1/SvJ 		abnormal cell physiology J:198482
decreased cellular sensitivity to gamma-irradiation J:198482
decreased thymocyte apoptosis J:198482
increased carcinoma incidence J:198482
increased T cell derived lymphoma incidence J:198482
increased teratoma incidence J:198482
increased tumor incidence J:198482
oxidative stress J:198482
premature death J:198482
Trp53tm1Tyj/Trp53+
involves: 129 * 129S2/SvPas * C57BL/6J 		normal neoplasm J:243104
Trp53tm1Tyj/Trp53+
involves: 129P2/OlaHsd * 129S2/SvPas * BALB/c * C57BL/6 		decreased survivor rate J:109193
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas 		abnormal hematopoietic system physiology J:158953
decreased cellular sensitivity to gamma-irradiation J:259337
decreased thymocyte apoptosis J:158953
increased carcinoma incidence J:95316
increased fibroblast proliferation J:95316
increased incidence of tumors by chemical induction J:170769
increased tumor incidence J:95316
increased urinary system tumor incidence J:170769
premature death J:95316
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * BALB/cJ * C57BL/6 		abnormal tumor incidence J:191827
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * C57BL/6 		abnormal iron level J:244082
abnormal tumor morphology J:17728
decreased tumor-free survival time J:17728, J:135509
gastric polyps J:72391
increased adenocarcinoma incidence J:72391
increased adenoma incidence J:72391
increased carcinoma incidence J:72391, J:95318
increased fibrosarcoma incidence J:17728
increased hemangiosarcoma incidence J:17728, J:72391
increased histiocytic sarcoma incidence J:72391
increased leiomyosarcoma incidence J:17728
increased leukemia incidence J:135509
increased lung adenocarcinoma incidence J:72391
increased lymphoma incidence J:17728, J:72391
increased mammary adenocarcinoma incidence J:72391
increased osteosarcoma incidence J:17728, J:72391
increased pancreas tumor incidence J:72391
increased rhabdomyosarcoma incidence J:17728
increased sarcoma incidence J:17728, J:72391, J:95318
increased squamous cell carcinoma incidence J:72391
increased tumor incidence J:17728, J:135509
intestine polyps J:72391
premature death J:95318
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * C57BL/6 * CBA 		decreased thymocyte apoptosis J:80311
premature death J:80311
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * C57BL/6 * FVB/N 		premature death J:216929
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * C57BL/6J 		abnormal tumor incidence J:108701
abnormal tumor latency J:108701
Trp53tm1Tyj/Trp53tm1.1Dgk
involves: 129S * 129X1/SvJ * C57BL/6 		delayed cellular replicative senescence J:180576
increased cell proliferation J:180576
Trp53tm1Tyj/Trp53tm1.1Umol
involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6 * C57BL/6NTac 		abnormal mesenchyme morphology J:228632
decreased cellular sensitivity to gamma-irradiation J:228632
decreased tumor latency J:228632
increased B cell derived lymphoma incidence J:228632
increased carcinoma incidence J:228632
increased hematopoietic stem cell number J:228632
increased leukemia incidence J:228632
increased lymphoma incidence J:228632
increased reproductive system tumor incidence J:228632
increased sarcoma incidence J:228632
increased T cell derived lymphoma incidence J:228632
premature death J:228632
Trp53tm1Tyj/Trp53tm1Tyj
129-Trp53tm1Tyj/J 		abnormal retina vasculature morphology J:55873
Trp53tm1Tyj/Trp53tm1Tyj
129S6.129-Trp53tm1Tyj Rb1tm1.1Jyjw 		increased lymphoma incidence J:102483
increased teratoma incidence J:102483
increased testicular teratoma incidence J:102483
intestinal ulcer J:102483
premature death J:102483
weight loss J:102483
Trp53tm1Tyj/Trp53tm1Tyj
B6.129S2-Trp53tm1Tyj/J 		abnormal ocular fundus morphology J:55873
abnormal optic nerve morphology J:55873
abnormal posterior eye segment morphology J:55873
abnormal retina vasculature morphology J:55873
increased opacity of vitreous body J:55873
optic nerve degeneration J:55873
optic nerve hypoplasia J:55873
retina fold J:55873
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129 * 129S2/SvPas * C57BL/6J 		normal neoplasm J:243104
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas 		abnormal cardiovascular system physiology J:120332
abnormal cell cycle checkpoint function J:77907, J:126920
abnormal neuron differentiation J:102702
cardiac hypertrophy J:120332
decreased cellular sensitivity to ultraviolet irradiation J:77907
decreased splenocyte apoptosis J:195018
decreased T cell apoptosis J:109354
decreased thymocyte apoptosis J:126920, J:158953, J:195018
decreased tumor-free survival time J:132597
increased angiogenesis J:120332
increased fibroblast proliferation J:77907
increased hemangiosarcoma incidence J:95316
increased lymphoma incidence J:221224
increased medulloblastoma incidence J:102702
increased T cell derived lymphoma incidence J:88120, J:95316, J:221224, J:251434
increased tumor incidence J:95316
polyploidy J:109354
premature death J:88120, J:95316
prenatal lethality, incomplete penetrance J:95316
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6J 		decreased tumor incidence J:104347
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * BALB/c 		increased cellular sensitivity to ionizing radiation J:116176
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL/6 		abnormal apoptosis J:87501
abnormal iron homeostasis J:244082
abnormal iron level J:244082
abnormal mitochondrial morphology J:244082
abnormal protein level J:244082
aneuploidy J:87501
colon polyps J:72391
decreased cell proliferation J:170976
decreased cellular sensitivity to gamma-irradiation J:95318
decreased cellular sensitivity to ultraviolet irradiation J:170976
decreased tumor-free survival time J:87501
gastric polyps J:72391
increased carcinoma incidence J:72391
increased fibroblast proliferation J:95318
increased fibrosarcoma incidence J:72391
increased hemangioma incidence J:72391
increased hemangiosarcoma incidence J:17728, J:72391
increased lymphoma incidence J:17728, J:72391, J:95318
increased osteosarcoma incidence J:17728, J:72391
increased rhabdomyosarcoma incidence J:17728
increased sarcoma incidence J:17728, J:72391, J:95318
increased squamous cell carcinoma incidence J:72391
increased T cell derived lymphoma incidence J:17728, J:87501
increased teratoma incidence J:17728
increased tumor incidence J:17728, J:72391
premature death J:72391, J:95318
preweaning lethality, incomplete penetrance J:17728
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL/6 * CBA 		decreased thymocyte apoptosis J:80311
premature death J:80311
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL/6 * FVB/N 		decreased mortality induced by ionizing radiation J:216929
premature death J:216929
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * FVB/N 		decreased cellular sensitivity to ionizing radiation J:114161
decreased sensitivity to skin irradiation J:114161
Trp53tm1Tyj/Trp53tm2.1Tyj
involves: 129S2/SvPas * 129S4/SvJae 		increased carcinoma incidence J:95316
increased hemangiosarcoma incidence J:95316
increased T cell derived lymphoma incidence J:95316
increased tumor incidence J:95316
premature death J:95316
prenatal lethality, incomplete penetrance J:95316
Trp53tm1Tyj/Trp53tm2.1Umol
involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6 * C57BL/6NTac 		decreased cellular sensitivity to gamma-irradiation J:228632
increased B cell derived lymphoma incidence J:228632
increased carcinoma incidence J:228632
increased hematopoietic stem cell number J:228632
increased lymphoma incidence J:228632
increased reproductive system tumor incidence J:228632
increased sarcoma incidence J:228632
increased T cell derived lymphoma incidence J:228632
premature death J:228632
Trp53tm1Tyj/Trp53tm3.1Glo
involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6 		premature death J:95318
Trp53tm1Tyj/Trp53tm3.1Tyj
involves: 129S2/SvPas * 129S4/SvJae 		increased carcinoma incidence J:95316
increased T cell derived lymphoma incidence J:95316
increased tumor incidence J:95316
premature death J:95316
prenatal lethality, incomplete penetrance J:95316
Trp53tm1Wahl/Trp53tm1Wahl
involves: 129S4/SvJae 		abnormal cell cycle J:64367, J:100189
decreased cellular sensitivity to gamma-irradiation J:64367
increased fibroblast proliferation J:64367
Trp53tm1Wahl/Trp53tm1Wahl
involves: C57BL/6 		decreased fibroblast apoptosis J:108183
increased tumor incidence J:108183
Trp53tm1Xu/Trp53tm1Xu
involves: 129S4/SvJae 		abnormal thymocyte apoptosis J:86185
decreased cellular sensitivity to ionizing radiation J:86185
decreased cellular sensitivity to ultraviolet irradiation J:86185
normal neoplasm J:86185
Trp53tm1Yjc/Trp53tm1Yjc
B6.129S1-Trp53tm1Yjc 		abnormal spleen marginal zone morphology J:195018
abnormal spleen white pulp morphology J:195018
decreased splenocyte apoptosis J:195018
enlarged liver J:195018
enlarged spleen J:195018
normal immune system phenotype J:195018
increased sarcoma incidence J:195018
increased splenic marginal zone lymphoma incidence J:195018
premature death J:195018
skin lesions J:195018
Trp53tm2.1Kasa/Trp53tm2.1Kasa
involves: 129P2/OlaHsd * C57BL/6 		normal cellular phenotype J:186335
normal mortality/aging J:186335
normal neoplasm J:186335
normal reproductive system phenotype J:186335
Trp53tm2.1Snj/Trp53+
involves: 129S4/SvJae * C57BL/6 		abnormal cell cycle J:175018
decreased cellular sensitivity to ionizing radiation J:175018
increased fibroblast proliferation J:175018
Trp53tm2.1Snj/Trp53tm2.1Snj
involves: 129S4/SvJae * C57BL/6 		abnormal cell cycle J:175018
abnormal thymus physiology J:175018
decreased cellular sensitivity to ionizing radiation J:175018
decreased cellular sensitivity to ultraviolet irradiation J:175018
delayed cellular replicative senescence J:175018
embryonic lethality during organogenesis, incomplete penetrance J:175018
exencephaly J:175018
increased fibroblast proliferation J:175018
lethality throughout fetal growth and development, incomplete penetrance J:175018
Trp53tm2.1Thst/Trp53+
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ 		premature death J:282255
Trp53tm2.1Thst/Trp53tm2.1Thst
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ 		abnormal tumor incidence J:282255
decreased tumor-free survival time J:282255
increased B cell derived lymphoma incidence J:282255
increased carcinoma incidence J:282255
increased sarcoma incidence J:282255
increased T cell derived lymphoma incidence J:282255
increased testis tumor incidence J:282255
Trp53tm2.1Tldo/Trp53tm2.1Tldo
involves: 129S2/SvPas * BALB/c * C57BL/6 		normal mortality/aging J:199308
Trp53tm2.1Tyj/Trp53+
involves: 129S4/SvJae 		decreased cellular sensitivity to gamma-irradiation J:95316
increased cell proliferation J:95316
increased metastatic potential J:95316
osteopetrosis J:95316
premature death J:95316
Trp53tm2.1Umol/Trp53tm2.1Umol
involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac 		increased B cell derived lymphoma incidence J:228632
increased T cell derived lymphoma incidence J:228632
premature death J:228632
Trp53tm2.1Wgu/Trp53tm2.1Wgu
involves: 129S6/SvEvTac * C57BL/6 		abnormal cell cycle J:186159
normal cellular phenotype J:186159
decreased thymocyte apoptosis J:186159
delayed cellular replicative senescence J:186159
increased fibroblast proliferation J:186159
normal neoplasm J:186159
Trp53tm2Att/Trp53tm2Att
either: (involves: 129S4/SvJae) or (involves: 129S4/SvJae * C57BL/6) 		abnormal cell cycle J:131856
decreased cellular sensitivity to ultraviolet irradiation J:131856
early cellular replicative senescence J:131856
Trp53tm2Glo/Trp53tm2Glo
involves: 129/Sv * C57BL/6 		abnormal apoptosis J:87501
decreased tumor-free survival time J:87501
increased lymphoma incidence J:87501
increased sarcoma incidence J:87501
increased tumor incidence J:87501
Trp53tm2Holl/Trp53tm2Holl
involves: 129P2/OlaHsd 		no abnormal phenotype detected J:135505
Trp53tm2Mok/Trp53+
involves: 129S/SvEv * C57BL/6 		decreased cellular sensitivity to ultraviolet irradiation J:106931
Trp53tm2Mok/Trp53tm2Mok
involves: 129S/SvEv * C57BL/6 		increased tumor incidence J:79629
Trp53tm2Thst/Trp53+
involves: 129S1/Sv * 129X1/SvJ 		premature death J:282255
Trp53tm2Thst/Trp53tm2.1Thst
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ 		abnormal tumor incidence J:282255
decreased tumor-free survival time J:282255
increased B cell derived lymphoma incidence J:282255
increased carcinoma incidence J:282255
increased sarcoma incidence J:282255
increased T cell derived lymphoma incidence J:282255
increased testis tumor incidence J:282255
Trp53tm2Tyj/Trp53tm2Tyj
involves: 129S4/SvJae 		early cellular replicative senescence J:175978
Trp53tm2Wahl/Trp53tm2Wahl
involves: 129S4/SvJae * C57BL/6 		abnormal definitive hematopoiesis J:174375
abnormal hematopoietic stem cell physiology J:174375
abnormal megakaryocyte progenitor cell morphology J:174375
decreased bone marrow cell number J:174375
decreased common myeloid progenitor cell number J:174375
decreased erythrocyte cell number J:174375
decreased erythroid progenitor cell number J:174375
decreased hematocrit J:174375
decreased leukocyte cell number J:174375
decreased spleen red pulp amount J:174375
enlarged heart J:174375
increased heart weight J:174375
increased mortality induced by ionizing radiation J:174375
normal mortality/aging J:174375
pallor J:174375
thrombocytopenia J:174375
Trp53tm2Xu/Trp53tm2Xu
involves: 129S6/SvEvTac 		decreased T cell apoptosis J:109354
decreased T cell proliferation J:109354
increased tumor incidence J:109354
increased tumor latency J:109354
Trp53tm3.1Glo/Trp53+
B6.129S7-Trp53tm3.1Glo 		abnormal cell cycle J:95318
decreased body weight J:317504
decreased cellular sensitivity to gamma-irradiation J:95318
extramedullary hematopoiesis J:317504
hepatosplenomegaly J:317504
increased B cell derived lymphoma incidence J:317504
increased carcinoma incidence J:95318, J:317504
increased fibroblast proliferation J:95318
increased leukocyte cell number J:317504
increased lymphoma incidence J:95318, J:317504
increased metastatic potential J:95318
increased osteosarcoma incidence J:317504
increased sarcoma incidence J:95318, J:317504
increased T cell derived lymphoma incidence J:317504
macrocytic anemia J:317504
premature death J:95318, J:317504
Trp53tm3.1Glo/Trp53tm3.1Glo
B6.129S7-Trp53tm3.1Glo 		increased DNA replication J:95318
increased fibroblast proliferation J:95318
increased lymphoma incidence J:95318
increased sarcoma incidence J:95318
premature death J:95318, J:317504
prenatal lethality, incomplete penetrance J:317504
Trp53tm3.1Glo/Trp53tm4Glo
involves: 129S7/SvEvBrd * C57BL/6 		abnormal tumor morphology J:171821
decreased tumor-free survival time J:171821
increased adenocarcinoma incidence J:171821
increased lymphoma incidence J:171821
increased sarcoma incidence J:171821
increased spindle cell carcinoma incidence J:171821
Trp53tm3.1Glo/Trp53tm4Glo
Tg(CAG-cre/Esr1*)5Amc/0
involves: 129S7/SvEvBrd * C57BL/6 * CBA 		abnormal tumor pathology J:171821
decreased tumor growth/size J:171821
extended life span J:171821
Trp53tm3.1Tyj/Trp53+
involves: 129S4/SvJae 		decreased cellular sensitivity to gamma-irradiation J:95316
increased B cell derived lymphoma incidence J:95316
increased carcinoma incidence J:95316
increased cell proliferation J:95316
increased hepatocellular carcinoma incidence J:95316
increased lung adenocarcinoma incidence J:95316
increased metastatic potential J:95316
increased squamous cell carcinoma incidence J:95316
increased tumor incidence J:95316
premature death J:95316
Trp53tm3.1Tyj/Trp53+
involves: 129S4/SvJae * SKH1 		increased mammary adenocarcinoma incidence J:121734
increased skin tumor incidence J:121734
Trp53tm3Att/Trp53tm3Att
involves: 129S4/SvJae 		normal cellular phenotype J:173395
Trp53tm3Att/Trp53tm3Att
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/?
involves: 129S4/SvJae 		normal cellular phenotype J:173395
Trp53tm3Tyj/Trp53+
Tg(Wap-cre)11738Mam/0
involves: 129S4/SvJae * C57BL/6 * SJL 		increased incidence of tumors by chemical induction J:101617
increased lung tumor incidence J:101617
increased lymphoma incidence J:101617
increased mammary adenocarcinoma incidence J:101617
increased mammary gland tumor incidence J:101617
increased sarcoma incidence J:101617
premature death J:101617
Trp53tm3Tyj/Trp53+
Tg(KRT14-cre)8Brn/?
involves: 129S4/SvJae * FVB/N * SKH1 		decreased cellular sensitivity to ultraviolet irradiation J:121734
increased hemangioma incidence J:121734
increased lymphoma incidence J:121734
increased skin tumor incidence J:121734
Trp53tm3Tyj/Trp53tm3Tyj
involves: 129S4/SvJae 		early cellular replicative senescence J:175978
Trp53tm3Wahl/Trp53tm3Wahl
involves: 129S4/SvJae 		abnormal cell cycle J:108183, J:118244
decreased apoptosis J:108183, J:118244
decreased cellular sensitivity to gamma-irradiation J:118244
increased cell proliferation J:108183
increased tumor latency J:108183
normal mortality/aging J:108183
Trp53tm3Xu/Trp53tm3Xu
Not Specified 		increased cellular sensitivity to ionizing radiation J:112302
normal mortality/aging J:112302
Trp53tm4.1Glo/Trp53tm4.1Glo
involves: 129S7/SvEvBrd * C57BL/6 		normal mortality/aging J:171821
normal neoplasm J:171821
Trp53tm4Att/Trp53tm4Att
involves: 129S4/SvJae 		decreased cellular sensitivity to gamma-irradiation J:173395
Trp53tm4Att/Trp53tm4Att
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/?
involves: 129S4/SvJae 		decreased apoptosis J:173395
Trp53tm4Glo/Trp53tm4Glo
involves: 129S7/SvEvBrd * C57BL/6 		decreased tumor-free survival time J:171821
increased adenocarcinoma incidence J:171821
increased lymphoma incidence J:171821
increased sarcoma incidence J:171821
increased spindle cell carcinoma incidence J:171821
increased T cell derived lymphoma incidence J:171821
Trp53tm4Tyj/Trp53tm4Tyj
involves: 129S4/SvJae * C57BL/6 		decreased cellular sensitivity to gamma-irradiation J:92917
increased B cell derived lymphoma incidence J:92917
increased sarcoma incidence J:92917
premature death J:92917
Trp53tm4Xu/Trp53+
Not Specified 		normal cellular phenotype J:160414
normal neoplasm J:126497
Trp53tm4Xu/Trp53tm4Xu
Not Specified 		abnormal cell cycle checkpoint function J:126497
abnormal tumor incidence J:126497
decreased apoptosis J:126497
decreased tumor-free survival time J:126497
increased lymphoma incidence J:126497
increased sarcoma incidence J:126497
increased T cell derived lymphoma incidence J:126497
increased tumor incidence J:126497
spontaneous chromosome breakage J:126497
Trp53tm5Tyj/Trp53tm5Tyj
involves: 129S4/SvJae 		abnormal cell cycle J:96433
abnormal cell death J:96433, J:118233
abnormal chromosome number J:118233
Trp53tm5Tyj/Trp53tm5Tyj
involves: 129S4/SvJae 		normal cellular phenotype J:96433
Trp53tm5Wahl/Trp53tm5Wahl
involves: 129S4/SvJae 		normal cellular phenotype J:118244
normal mortality/aging J:118244
Trp53tm5Xu/Trp53tm5Xu
Not Specified 		decreased apoptosis J:126497
spontaneous chromosome breakage J:126497
Trp53tm6Wahl/Trp53tm6Wahl
involves: 129S4/SvJae 		normal cellular phenotype J:118244
normal mortality/aging J:118244
Trp53tm6Xu/Trp53tm6Xu
Tg(Lck-cre)1Cwi/0
involves: 129S4/SvJae 		decreased tumor-free survival time J:157041
increased lymphoma incidence J:157041
increased metastatic potential J:157041
increased T cell derived lymphoma incidence J:157041
Trp53tm7.1Xu/Trp53+
Not Specified 		abnormal cell cycle checkpoint function J:160414
abnormal thymus physiology J:160414
chromosomal instability J:160414
Trp53tm7.1Xu/Trp53tm7.1Xu
Not Specified 		abnormal cell cycle checkpoint function J:160414
abnormal thymus physiology J:160414
chromosomal instability J:160414
decreased thymocyte apoptosis J:160414
increased lymphoma incidence J:160414
increased sarcoma incidence J:160414
increased tumor incidence J:160414
premature death J:160414
Trp53tm8Xu/Trp53tm8Xu
Not Specified 		preweaning lethality, complete penetrance J:170216
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
Tg(tetO-RNAi:Trp53)ASlowe/0
involves: C57BL/6 * CD-1 		increased metastatic potential J:199542
increased osteosarcoma incidence J:199542
premature death J:199542
Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
10/29/2024
MGI 6.24 		The Jackson Laboratory